Filters

anti-CD170 / SIGLEC5 Antibody

anti-CD170 / SIGLEC5 Antibody size: 0,1 mg 543

Supplier ACR
Price 543
Size 0,1 mg
Vial description OB-binding protein 2, OBBP2, Siglec-5, CD33L2
Categoryprimary antibody
Clonalitymonoclonal
Raised inRat
Clone8D2
FormAzide Free
ReactivityMouse
Puritypurified
Molecular weightin kDa
Sourcemammalian
Activityto be determined
Rangebroad
Protein numberO15389
Application IP, F
Storage Avoid freeze/thaw cycles, Upon delivery aliquot and store at -20°, C, C for one year, Shipped at 4°
Description Freeze thaw will destroy a percentage in every cycle and should be avoided, C in a fridge short term in a concentrated dilution, This antibody needs to be stored at + 4°
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by acr they should be stored frozen at - 24°
Gene targetCD170 / SIGLEC5
Short nameanti-CD170 / SIGLEC5 Antibody
Technique antibodies against human proteins, antibodies for, antibody to, Antibody
Alternative nameantibody to-CD170 / Sialic acid-binding Ig-like lectin 5 (Antibody to)
Alternative techniqueantibodies
Alternative to gene target CD170 and CD33L2 and OB-BP2 and OBBP2 and SIGLEC-5, Plasma membranes, SIGLEC5 and IDBG-728530 and ENSG00000268500 and 8778, protein binding, this GO :0005515 and protein binding and molecular function this GO :0007155 and cell adhesion and biological process this GO :0016021 and integral component of membrane and cellular component, this GO :0005515: protein binding, this GO :0005515: protein binding, Sialic acid-binding Ig-like lectin 5
Identity 10874
Gene SIGLEC5
Long gene name sialic acid binding Ig like lectin 5
Synonyms gene CD33L2
Synonyms gene name sialic acid binding Ig-like lectin 5
Synonyms OB-BP2 SIGLEC-5 CD170
Locus 19q13, 41
Discovery year 1998-12-16
GenBank acession U71383
Entrez gene record 8778
Pubmed identfication 10343116
RefSeq identity NM_003830
Classification CD molecules Sialic acid binding Ig like lectins V-set domain containing
Havana BLAST/BLAT OTTHUMG00000165510

Subscribe to our Newsletter